Protecting your inventions: the patent system

Webber, Philip

doi:10.1038/nrd1200

Cited by 23 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We have been unable to find any formal description of the information flow between these two document types but it can be briefly described as follows. Drug discovery project teams typically apply for patents to claim and protect the chemical space around their lead series from which clinical development candidates may be chosen [9]. This sets the minimum time between the generation of data and its disclosure to 18 months.…”

Section: Introductionmentioning

confidence: 99%

Tracking 20 Years of Compound-to-Target Output from Literature and Patents

Southan¹,

Várkonyi

Boppana³

et al. 2013

PLoS ONE

View full text Add to dashboard Cite

The statistics of drug development output and declining yield of approved medicines has been the subject of many recent reviews. However, assessing research productivity that feeds development is more difficult. Here we utilise an extensive database of structure-activity relationships extracted from papers and patents. We have used this database to analyse published compounds cumulatively linked to nearly 4000 protein target identifiers from multiple species over the last 20 years. The compound output increases up to 2005 followed by a decline that parallels a fall in pharmaceutical patenting. Counts of protein targets have plateaued but not fallen. We extended these results by exploring compounds and targets for one large pharmaceutical company. In addition, we examined collective time course data for six individual protease targets, including average molecular weight of the compounds. We also tracked the PubMed profile of these targets to detect signals related to changes in compound output. Our results show that research compound output had decreased 35% by 2012. The major causative factor is likely to be a contraction in the global research base due to mergers and acquisitions across the pharmaceutical industry. However, this does not rule out an increasing stringency of compound quality filtration and/or patenting cost control. The number of proteins mapped to compounds on a yearly basis shows less decline, indicating the cumulative published target capacity of global research is being sustained in the region of 300 proteins for large companies. The tracking of six individual targets shows uniquely detailed patterns not discernible from cumulative snapshots. These are interpretable in terms of events related to validation and de-risking of targets that produce detectable follow-on surges in patenting. Further analysis of the type we present here can provide unique insights into the process of drug discovery based on the data it actually generates.

show abstract

Section: Introductionmentioning

confidence: 99%

Tracking 20 Years of Compound-to-Target Output from Literature and Patents

Southan¹,

Várkonyi

Boppana³

et al. 2013

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Despite the fact that international consensus is lacking on how biotechnology has to be treated, the biotechnology innovators opt for patenting their invention. Webber (2003) has insisted that research outcomes of pharmaceutical sector, any biotech start-up or academia should be protected by patents. This is because enormous efforts, hard work, and financial inputs are needed to develop a novel drug or product out of hundreds and thousands of lead compounds.…”

Section: What Is Intellectual Property?mentioning

confidence: 99%

Intellectual Property Rights in Animal Biotechnology

Singh

Mal

Gautam

et al. 2019

Advances in Animal Biotechnology

View full text Add to dashboard Cite

Intellectual property is the foundation of innovations. The science of animal biotechnology has progressed vastly during past three decades. Vaccines, antibodies, gene-editing, or transgenic animals as model for investigating human diseases and producing recombinant therapeutics, and the bioinformatics methods are the innovative intellectual outcomes. Highlights• Animal biotechnology is oriented toward developing products at commercial scale • IPRs are essential components of animal biotechnology research and development.

show abstract

“…In the US, inventions must be useful and contain an element of novelty that would not be obvious to a person reasonably skilled in the art. 32 In addition, "theoretical" inventions that have never actually been created are still patentable. 33 To file a patent in the European Patent Office (EPO), the invention must be new, contain an inventive step, and be "susceptible of industrial application."…”

Section: Determining Patentabilitymentioning

confidence: 99%

“…The claims are the most important section of a patent application. 32 They comprise the "legal section" of the patent, and indicate the scope and the coverage of the patent. A wide scope of patent claims has been shown to enhance functionality development and increase productivity of the technology.…”

Section: Patent Applicationsmentioning

confidence: 99%

Patent protection and licensing in microfluidics

Yetisen

Volpatti

2014

Lab Chip

View full text Add to dashboard Cite

Microfluidic devices offer control over low-volume samples in order to achieve high-throughput analysis, and reduce turnaround time and costs. Their efficient commercialisation has implications for biomedical sciences, veterinary medicine, environmental monitoring and industrial applications. In particular, market diffusion of microfluidic laboratory and point-of-care diagnostic devices can contribute to the improvement of global health. In their commercialisation, consultancy and patent protection are essential elements that complement academic publishing. The awareness of knowledge transfer strategies can help academics to create value for their research. The aim of this article is to provide a guidance to (1) overview the terminology in patent law, (2) elucidate the process of filing a patent in the US, EU, Japan and internationally, (3) discuss strategies to licence a patent, and (4) explain tactics to defend a patent in a potential infringement. Awareness of the patent law and rights allows obtaining optimised, valid and valuable patents, while accelerating implementation to market route. Striking a balance between academic publishing, consultancy to industry and patent protection can increase commercial potential, enhance economic growth and create social impact.

show abstract

Protecting your inventions: the patent system

Cited by 23 publications

References 0 publications

Tracking 20 Years of Compound-to-Target Output from Literature and Patents

Tracking 20 Years of Compound-to-Target Output from Literature and Patents

Intellectual Property Rights in Animal Biotechnology

Patent protection and licensing in microfluidics

Contact Info

Product

Resources

About